Stock Financial Ratios, Dividends, Split History

ALBO / Albireo Pharma, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)411.04
Enterprise Value ($M)207.86
Book Value ($M)160.17
Book Value / Share13.41
Price / Book2.57
NCAV ($M)142.28
NCAV / Share11.91
Price / NCAV2.82
Share Statistics
Common Shares Outstanding 11,897,146
Preferred Stock Shares Outstanding 0
Common Stock Shares Outstanding 8,902,784
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.37
Return on Assets (ROA)-0.85
Return on Equity (ROE)-0.92
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio27.25
Income Statement (mra) ($M)
Revenue From Grants0.00
Sales Revenue Goods Net1,000.00
Operating Income-24.58
Net Income-24.41
Earnings Per Share Basic And Diluted-3.12
Earnings Per Share Diluted-3.12
Earnings Per Share Basic-3.12
Cash Flow Statement (mra) ($M)
Cash From Operations-27.57
Cash from Investing4.31
Cash from Financing-27.57
Identifiers and Descriptors
Central Index Key (CIK)1322505

Split History

Stock splits are used by Albireo Pharma, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Why Wedbush Sees Albireo More Than Doubling

2018-06-13 247wallst
Albireo Pharma, Inc. (NASDAQ: ALBO) recently received some positive news from the U.S. Food and Drug Administration (FDA) and it could have huge implications for the stock. One analyst actually sees the stock more than doubling as a result of this news. (8-0)

FDA Grants Rare Pediatric Disease Designation to Albireo’s Liver Disease Drug

2018-06-12 biospace
The U.S. Food and Drug Administration (FDA) granted Boston-based Albireo Pharma’s A4250 rare pediatric disease designation. (7-0)

Albireo Pharma's (ALBO) CEO Ron Cooper on Q1 2018 Results - Earnings Call Transcript

2018-05-17 seekingalpha
Greetings and welcome to Albireo’s First Quarter 2018 Earnings Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder this conference is being recorded. I would now like to turn the conference over to Paul Arndt. Sir, you may begin. (7-1)

Biotech Forum: The Week Ahead

2018-04-09 seekingalpha
There are numerous small cap names presenting mid-stage trial results in the week ahead which could move their stocks. (193-2)

CUSIP: 09064M204